ANN D. RHOADS - 27 May 2022 Form 4 Insider Report for QuidelOrtho Corp (QDEL)

Role
Director
Signature
/s/ Phillip S. Askim, attorney-in-fact for Ann D. Rhoads
Issuer symbol
QDEL
Transactions as of
27 May 2022
Net transactions value
$0
Form type
4
Filing time
01 Jun 2022, 17:39:39 UTC
Previous filing
20 May 2022
Next filing
08 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QDEL Common Stock Award +2,248 2,248 27 May 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QDEL Restricted Stock Units Award $0 +427 $0.000000 427 27 May 2022 Common Stock 427 Direct F2, F3, F4
transaction QDEL Restricted Stock Units Award $0 +128 $0.000000 128 27 May 2022 Common Stock 128 Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc, QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each share of common stock of Quidel beneficially owned by the Reporting Person at the effective time of the transaction contemplated by the Business Combination Agreement was exchanged for one share of common stock of QuidelOrtho.
F2 Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock.
F3 Pursuant to the Business Combination Agreement, the Quidel restricted stock units were converted into an equal number of restricted stock units representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions).
F4 Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and will occur according to the elected deferral schedule.